Novavax

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 1.5K

Market Cap: $1.7B

Website

Introduction: Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Clinical Trials

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Phase 2

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
Other: Placebo

First Posted Date: 2022-07-21

Last Posted Date: 2024-12-20

Lead Sponsor: Novavax

Target Recruit Count: 3600

Registration Number: NCT05468736

Locations: 🇺🇸
Tekton Research Beaumont, Beaumont, Texas, United States
🇺🇸
Research Your Health, Plano, Texas, United States
🇺🇸
Morehouse School of Medicine, Atlanta, Georgia, United States

and more 91 locations

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Phase 3

Completed

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Drug: NVX-Cov2373

First Posted Date: 2022-07-18

Last Posted Date: 2023-07-20

Lead Sponsor: Novavax

Target Recruit Count: 911

Registration Number: NCT05463068

Locations: 🇺🇸
Long Beach Clinical Trial Services Inc., Long Beach, California, United States
🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸
MedPharmics, Gulfport, Mississippi, United States

and more 15 locations

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines

Phase 3

Completed

Conditions: COVID-19
SARS CoV 2 Infection

Interventions: Drug: NVX-CoV2515
Drug: NVX-CoV2373 + NVX-CoV2515
Drug: NVX-CoV2540
Drug: NVX-CoV2373 + NVX-CoV2540
Drug: NVX-Cov2373

First Posted Date: 2022-05-12

Last Posted Date: 2024-04-23

Lead Sponsor: Novavax

Target Recruit Count: 1340

Registration Number: NCT05372588

Locations: 🇦🇺
Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia
🇦🇺
Paratus Clinical Research Brisbane, Albion, Queensland, Australia
🇦🇺
Emeritus Research, Camberwell, Victoria, Australia

and more 15 locations

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)

Phase 2

Completed

Conditions: SARS-CoV-2 Infection

Interventions: Biological: NVX-CoV2373

First Posted Date: 2021-11-09

Last Posted Date: 2023-03-16

Lead Sponsor: Novavax

Target Recruit Count: 384

Registration Number: NCT05112848

Locations: 🇿🇦
KwaPhila Health Solutions (Enhancing Care), Westridge, Durban, South Africa
🇿🇦
Josha Research, Bloemfontein, Free State, South Africa
🇿🇦
The Aurum Institute Pretoria Clinical Research Services, Pretoria, Gauteng, South Africa

and more 4 locations

Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults

Phase 1

Withdrawn

Conditions: Covid19

Interventions: Biological: SII B.1.351
Biological: SII Bivalent
Biological: SII B.1.617.2

First Posted Date: 2021-09-01

Last Posted Date: 2022-05-31

Lead Sponsor: Novavax

Registration Number: NCT05029856

Locations: 🇦🇺
University Hospital Geelong-Barwon Health, Geelong, Victoria, Australia
🇦🇺
Holdsworth House Medical Practice - Sydney, Sydney, New South Wales, Australia
🇦🇺
Australian Clinical Research Network (ACRN), Maroubra, New South Wales, Australia

and more 1 locations

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine

Phase 1

Completed

Conditions: Covid19
SARS-CoV Infection

Interventions: Biological: ICC Vaccine
Biological: qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant
Biological: SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant

First Posted Date: 2021-07-14

Last Posted Date: 2022-07-22

Lead Sponsor: Novavax

Target Recruit Count: 642

Registration Number: NCT04961541

Locations: 🇦🇺
Paratus Clinical Research - Canberra, Bruce, Australian Capital Territory, Australia
🇦🇺
Austrials Pty Ltd - Taringa, Taringa, Queensland, Australia
🇦🇺
Emeritus Research, Camberwell, Victoria, Australia

and more 7 locations

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Phase 3

Completed

Conditions: SARS-CoV Infection
Covid19

Interventions: Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Other: Placebo (Initial Vaccination Period)
Other: Placebo (Crossover Vaccination period)
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)

First Posted Date: 2020-11-02

Last Posted Date: 2023-12-21

Lead Sponsor: Novavax

Target Recruit Count: 33000

Registration Number: NCT04611802

Locations: 🇺🇸
Atlanta - Morehouse School of Medicine (Adult Site), Atlanta, Georgia, United States
🇺🇸
Synexus Clinical Research US, Inc (Adult Site), Chicago, Illinois, United States
🇺🇸
Beth Israel Deaconess Medical Center (Adult Site), Boston, Massachusetts, United States

and more 134 locations

A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

Phase 3

Completed

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Other: Placebo
Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant
Biological: Licensed seasonal influenza vaccine

First Posted Date: 2020-10-12

Last Posted Date: 2023-04-10

Lead Sponsor: Novavax

Target Recruit Count: 15138

Registration Number: NCT04583995

Locations: 🇬🇧
Royal Free (Site UK012), Hampstead, London, United Kingdom
🇬🇧
Synexus Wales Clinical Research Centre (Site UK025), Cardiff, United Kingdom
🇬🇧
The Royal Cornwall Hospitals NHS Trust (Site UK036), Truro, Cornwall, United Kingdom

and more 30 locations

A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults

Phase 2

Completed

Conditions: SARS-CoV-2 Infection
COVID-19

Interventions: Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Other: Placebo

First Posted Date: 2020-08-31

Last Posted Date: 2022-02-17

Lead Sponsor: Novavax

Target Recruit Count: 4422

Registration Number: NCT04533399

Locations: 🇿🇦
ZA014, Worcester, Western Cape, South Africa
🇿🇦
ZA020, Durban, KwaZulu-Natal, South Africa
🇿🇦
ZA018, Bloemfontein, Free State Of South Africa, South Africa

and more 11 locations

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

Phase 1

Completed

Conditions: COVID-19

Interventions: Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1
Other: Normal saline solution (NSS), Placebo - Phase 2
Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1
Other: Normal saline solution (NSS), Placebo - Phase 1
Biological: SARS-CoV-2 rS - Phase 1
Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1

First Posted Date: 2020-04-30

Last Posted Date: 2023-04-10

Lead Sponsor: Novavax

Target Recruit Count: 1419

Registration Number: NCT04368988

Locations: 🇺🇸
Rapid Medical Research Inc - ERN-PPDS - Phase 2, Cleveland, Ohio, United States
🇺🇸
Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Phase 2, Savannah, Georgia, United States
🇺🇸
Advanced Clinical Research - Meridian - ERN-PPDS - Phase 2, Meridian, Idaho, United States

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy